GB-19

N/A

Report date: 2026/04/01 15:18:04

Base Information

Drug NameGB-19
Drug Alias NameGB19GB-19
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-Type lectin domain family 4 member C modulators
TargetsC-Type lectin domain family 4 member C
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Kexing Bio-Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong Kexing Bio-Products Co LtdShenzhen Kexing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A